Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113652 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL110952 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111260 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL113653 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL109771 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111261 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111262 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111688 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111687 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C | |
| SCHEMBL111689 | 1.00 | NOD1 (0.51) | NOD1NAAAEPHX1TSHRHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424499-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | Abbott Laboratories (US) | 2012-03-07 | — | — | EP | claimed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | claimed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | claimed |
| US-8927009-B2 | ABT-263 capsule | ABBVIE INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8728516-B2 | Stabilized lipid formulation of apoptosis promoter | ABBVIE INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-8513243-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8362013-B2 | Salt of ABT-263 and solid-state forms thereof | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362014-B2 | ABT-263 crystalline forms | ABBVIE INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2515883-A1 | ABT-263 CAPSULE | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2477972-A1 | ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES | Abbott Laboratories (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2442789-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | Abbott Laboratories (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2011034934-A1 | ABT-263 CRYSTALLINE FORMS AND SOLVATES FOR USE IN TREATING BCL-2 PROTEIN RELATED DISEASES | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010147899-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | ABBOTT LABORATORIES (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBVIE INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES | 2010-11-25 | — | — | US | disclosed |
| WO-2010127198-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127193-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | ABBVIE INC. | 2010-11-04 | — | — | US | disclosed |
| WO-2010127190-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | ABBOTT LABORATORIES (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323020-A1 | STABLE NANOPARTICULATE DRUG SUSPENSION | BCL2L10, TMBIM6, BCOR | NOD1 1503/4885NAAA 4361/4885EPHX1 4611/4885 |
| US-20100297194-A1 | FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCL2L2 | NOD1 2124/4885NAAA 4756/4885EPHX1 4586/4885 |
| US-20100305125-A1 | SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF | BCL3, BCL2, BCL2L13 | NOD1 2221/4885NAAA 4230/4885EPHX1 4845/4885 |
| US-20100278905-A1 | STABILIZED LIPID FORMULATION OF APOPTOSIS PROMOTER | BCL2, BAX, BCOR | NOD1 2795/4885NAAA 4513/4885EPHX1 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.